BCMA-FAP chimeric antigen receptor T cells

BCMA-FAP chimeric antigen receptor T cells (BCMA-FAP CART) are an experimental dual-targeting cell therapy developed for the treatment of multiple myeloma. The therapy consists of T cells engineered via lentiviral transduction to express two distinct chimeric antigen receptors: one specific for B-cell maturation antigen (BCMA), which is highly expressed on malignant plasma cells, and another specific for fibroblast activation protein (FAP), which is expressed on cancer-associated fibroblasts (CAFs) within the bone marrow microenvironment. This dual-targeting strategy is designed to overcome resistance to conventional BCMA-directed CAR-T therapies by simultaneously eliminating the tumor cells and disrupting the immunosuppressive stroma that supports tumor growth and inhibits T-cell function. The FAP-targeting CAR component typically utilizes a 4-1BB costimulatory domain. Preclinical research, primarily conducted at the Mayo Clinic, has demonstrated that this approach can remodel the tumor microenvironment to enhance therapeutic efficacy.

Other names

BCMA-FAP dual-targeting CAR T cells